{"symbol":"BMY","fiscalQuarter":"Q2-2019","reportDate":"2019-07-25","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q2-2019","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Up 5.02%","keyNumbers":[{"metric":"EPS","actual":"$1.18","expected":"N/A","surprise":"+8.87%"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our EPS performance this quarter.","Our focus remains on advancing our pipeline and delivering value to patients."],"summary":"Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline advancements. They emphasized the importance of continuing to deliver value to patients."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's strong EPS performance exceeded expectations, which contributed to a positive stock reaction, with shares rising by 5.02%. The company did not provide any updates on future guidance, leaving investors to focus on the current results and the ongoing development of its product pipeline. This quarter's performance may bolster investor confidence as the company continues to navigate the competitive landscape in the pharmaceutical industry.","metaDescription":"Bristol Myers Squibb (BMY) Q2 2019 earnings: EPS beat by 8.87%. Stock up 5.02%. Full breakdown."}}